O
Olga Anczuków
Researcher at University of Connecticut Health Center
Publications - 37
Citations - 2079
Olga Anczuków is an academic researcher from University of Connecticut Health Center. The author has contributed to research in topics: RNA splicing & Alternative splicing. The author has an hindex of 15, co-authored 26 publications receiving 1545 citations. Previous affiliations of Olga Anczuków include International Agency for Research on Cancer & University of Connecticut.
Papers
More filters
Journal ArticleDOI
The splicing factor SRSF1 regulates apoptosis and proliferation to promote mammary epithelial cell transformation
Olga Anczuków,Avi Z. Rosenberg,Avi Z. Rosenberg,Martin Akerman,Shipra Das,Shipra Das,Lixing Zhan,Lixing Zhan,Rotem Karni,Rotem Karni,Senthil K. Muthuswamy,Senthil K. Muthuswamy,Adrian R. Krainer +12 more
TL;DR: SRSF 1 can promote breast cancer, and SRSF1 itself or its downstream effectors may be valuable targets for the development of therapeutics.
Journal ArticleDOI
SRSF1-Regulated Alternative Splicing in Breast Cancer.
Olga Anczuków,Martin Akerman,Antoine Cléry,Jie Wu,Chen Shen,Nitin H. Shirole,Amanda C. Raimer,Shuying Sun,Mads A. Jensen,Yimin Hua,Frédéric H.-T. Allain,Adrian R. Krainer +11 more
TL;DR: SRSF1 positive and negative regulatory mechanisms, and oncogenic AS events that represent potential targets for therapeutics development are uncovered.
Journal ArticleDOI
Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics
TL;DR: Current efforts in targeting alternative splicing are summarized, including global splicing inhibition using small molecules blocking the spliceosome or splicing‐factor‐modifying enzymes, as well as splice‐switching RNA‐based therapeutics to modulate cancer‐specific splicing isoforms.
Journal ArticleDOI
Splicing-factor alterations in cancers.
Olga Anczuków,Adrian R. Krainer +1 more
TL;DR: Current understanding of the role of splicing-factor alterations in human cancers is summarized, and recent efforts to develop novel cancer therapies based on targeting either the oncogenic splicing events or their upstream splicing regulators are summarized.
Journal ArticleDOI
Oncogenic Splicing Factor SRSF1 Is a Critical Transcriptional Target of MYC
TL;DR: It is shown that SRSF1 is a direct target of the transcription factor oncoprotein MYC, a critical MYC target that contributes to its oncogenic potential by enabling MYC to regulate the expression of specific protein isoforms through alternative splicing.